<p>Leiomyosarcoma (LMS) is a smooth muscle-derived mesenchymal cancer commonly found to have recurrent loss of tumor suppressor genes and a poorly defined oncogenic program. Empiric cytotoxic chemotherapy is the standard systemic treatment for LMS, and while more targeted and effective therapies are urgently needed, insights into therapeutic vulnerabilities in LMS have been limited by available preclinical models. We generated a panel of LMS patient-derived xenograft (PDX) models and evaluated fidelity to their tumors of origin using RNA sequencing and ultra-low passage whole-genome sequencing (ULP-WGS). Data available at dbGaP include RNA sequencing and ULP-WGS of primary tumors and early and late passages of PDX. </p>

Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to    Transcriptional CDK Inhibitors through Antagonism of E2F-Driven    Oncogenic Gene Expression

Leiomyosarcoma study with RNA-Seq, WGS data on dbGaP (11 participants)

phs002587 — Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to    Transcriptional CDK Inhibitors through Antagonism of E2F-Driven    Oncogenic Gene Expression

Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression

Description

Applying For Access

Summary